Article
Oncology
E. Felip, A. T. Shaw, A. Bearz, D. R. Camidge, B. J. Solomon, J. R. Bauman, T. M. Bauer, S. Peters, F. Toffalorio, A. Abbattista, H. Thurm, G. Peltz, R. Wiltshire, B. Besse
Summary: The study showed that lorlatinib had clinically meaningful intracranial and extracranial antitumor activity in ALK-positive NSCLC patients who had progressed on second-generation ALK TKIs. The efficacy was particularly notable in patients with fewer lines of therapy, with elevated intracranial ORR compared to extracranial ORR.
ANNALS OF ONCOLOGY
(2021)
Editorial Material
Oncology
Shelley Kuang, Natasha B. Leighl
Summary: The study in NEJM examined whether lorlatinib should be the standard first-line treatment for advanced ALK-rearranged lung cancer.
Article
Oncology
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Summary: This study found that glycogen synthase kinase 3 (GSK3) plays a crucial role in both intermediate and acquired resistance to lorlatinib in ALK-positive NSCLC. Inhibiting GSK3 can suppress the growth of resistant cells and make other resistant cells sensitive to lorlatinib.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Yasushi Goto, Takehito Shukuya, Ai Murata, Hironori Kikkawa, Birol Emir, Robin Wiltshire, Satoru Miura
Summary: This retrospective observational study investigated the clinical effectiveness of lorlatinib in second- or later-line settings after alectinib failure in Japanese patients. The study results support the effectiveness of lorlatinib after alectinib failure in Japanese patients.
Review
Oncology
Serena Ceddia, Giovanni Codacci-Pisanelli
Summary: Brain metastases are common in patients with ALK-translocated non-small cell lung cancer and are typically treated with radiotherapy. However, this can lead to severe late toxic side effects, prompting the use of ALK inhibitors such as crizotinib, alectinib, and brigatinib which have shown excellent activity against brain metastases. Starting treatment with specific inhibitors in asymptomatic patients and using radiotherapy when needed provides the best quality of life for patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Po-Hsin Lee, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang
Summary: This study retrospectively evaluated the efficacy and adverse events of lorlatinib treatment in 22 ALK-positive non-small cell lung cancer patients. The results showed that patients' progression-free survival was related to their history and responses of prior ALK inhibitor treatments.
Article
Oncology
Benjamin J. Solomon, Todd M. Bauer, Sai-Hong Ignatius Ou, Geoffrey Liu, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi-Long Wu, Oscar Arrieta, Jacek Jassem, Anna M. Calella, Gerson Peltz, Anna Polli, Holger Thurm, Tony Mok
Summary: In the CROWN trial, lorlatinib showed significant efficacy in previously untreated advanced ALK-positive non-small-cell lung cancer patients, regardless of the presence of brain metastases. Compared to crizotinib, lorlatinib improved progression-free survival and reduced the incidence of CNS progression. Most lorlatinib-related CNS adverse events were of mild severity, with half of the events resolving without intervention or with dose modification.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Saadettin Kilickap, Sertac Ak, Oldac U. Dursun, Mehmet A. N. Sendur, Nuri Karadurmus, Umut Demirci
Summary: Lorlatinib is an effective drug for the treatment of ALK-positive non-small cell lung cancer. However, it may have undesirable effects on the central nervous system, though these effects are generally mild and can be treated.
Review
Oncology
Keisuke Baba, Yasushi Goto
Summary: Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information about the characteristics and efficacy of lorlatinib, as well as the unexpected medical problems that may arise during treatment. The review discusses the current status of lorlatinib as a treatment for ALK-positive lung cancer and the future therapeutic challenges.
Article
Oncology
Florian Janke, Arlou Kristina Angeles, Anja Lisa Riediger, Simone Bauer, Martin Reck, Albrecht Stenzinger, Marc A. Schneider, Thomas Muley, Michael Thomas, Petros Christopoulos, Holger Sueltmann
Summary: This study demonstrates the potential of DNA methylation biomarkers in prognosis and therapy monitoring of ALK-positive NSCLC patients. The research highlights the suitability of cfDNA methylation as a non-invasive biomarker for tumor detection and its correlation with other genomic alterations.
CLINICAL EPIGENETICS
(2022)
Review
Oncology
Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai
Summary: ALK inhibitors have shown efficacy in treating ALK-positive NSCLC, but resistance development remains a challenge. The high cost of targeted inhibitors and potential for increased resistance to combination therapy are important issues to address. STK11 mutation may serve as a biomarker for immunotherapy in NSCLC. This review summarizes the role of STK11 in ALK-positive NSCLC and provides an overview of treatment and drug resistance studies.
Article
Multidisciplinary Sciences
Ruiqi Chen, Lilan Zhao, Juan Zhang, Lingwen Guo, Zhizhong Chen, Xiaojie Pan, Wenshu Chen
Summary: This case study presents a patient with initially unresectable stage III lung adenocarcinoma who achieved a radical resection and pathological complete response (pCR) through neoadjuvant therapy with lorlatinib. This suggests that utilizing ALK-TKIs as neoadjuvant therapy could be a viable choice for ALK-positive NSCLC patients.
Review
Oncology
Shrestha Nensi, John Ashton
Summary: Recent advances in the treatment of chromosomally rearranged ALK positive non-small cell lung cancer have significantly improved survival times, largely due to improvements in blood-brain barrier penetration and the broad effectiveness of drugs against ligand binding pocket mutations. However, the frequency of cancers with compound resistance mutations may slow down these advances, highlighting the need to develop multiple ALK inhibitors to target different compound mutations.
CURRENT CANCER DRUG TARGETS
(2021)
Article
Oncology
Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, Pascale Dubray-Longeras, Alexis B. Cortot, Renaud Descourt, Helene Doubre, Xavier Quantin, Michael Duruisseaux, Isabelle Monnet, Denis Moro-Sibilot, Jacques Cadranel, Christelle Clement-Duchene, Sophie Cousin, Charles Ricordel, Patrick Merle, Josiane Otto, Sophie Schneider, Alexandra Langlais, Franck Morin, Virginie Westeel, Nicolas Girard
Summary: In this study, the researchers evaluated the treatment sequencing, efficacy, and safety of lorlatinib in patients with ALK+ NSCLC through the French Expanded Access Program. The results showed that lorlatinib provided significant clinical benefit and high intracerebral antitumor activity in heavily pretreated patients with ALK+ NSCLC.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Julien Mazieres, Laura Iadeluca, Alice T. Shaw, Benjamin J. Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong-Wan Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna M. Polli, Geoffrey Liu
Summary: This study presents detailed patient-reported outcome data from a phase 3 study comparing lorlatinib with crizotinib in previously untreated ALK-positive advanced NSCLC patients. The results show that both drugs improved quality of life, functioning, and symptom scores during treatment. Lorlatinib showed better improvements in several symptoms, while crizotinib performed better in cognitive functioning.
Article
Chemistry, Analytical
Comtet-Louis Andriamanampisoa, Aurelien Bancaud, Audrey Boutonnet-Rodat, Audrey Didelot, Jacques Fabre, Frederic Fina, Fanny Garlan, Sonia Garrigou, Caroline Gaudy, Frederic Ginot, Daniel Henaff, Pierre Laurent-Puig, Arnaud Morin, Vincent Picot, Laure Saias, Valerie Taly, Pascale Tomasini, Aziz Zaanan
ANALYTICAL CHEMISTRY
(2018)
Article
Medical Laboratory Technology
Diane Frankel, Isabelle Nanni-Metellus, Andree Robaglia-Schlupp, Pascale Tomasini, Julien Guinde, Fabrice Barlesi, Philippe Astoul, L'Houcine Ouafik, Florent Amatore, Veronique Secq, Elise Kaspi, Patrice Roll
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2018)
Article
Medicine, General & Internal
L. Horn, A. S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. J. Hochmair, F. Huemer, G. Losonczy, M. L. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. S. Shames, J. Liu, B. Ding, A. Lopez-Chavez, F. Kabbinavar, W. Lin, A. Sandler, S. V. Liu
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Oncology
Pascale Tomasini, Celine Mascaux, Kevin Jao, Catherine Labbe, Suzanne Kamel-Reid, Tracy Stockley, David M. Hwang, Natasha B. Leighl, Geoffrey Liu, Penelope A. Bradbury, Melania Pintilie, Ming-Sound Tsao, Frances A. Shepherd
CLINICAL LUNG CANCER
(2019)
Article
Oncology
Mathieu Grangeon, Pascale Tomasini, Solene Chaleat, Arnaud Jeanson, Maxime Souquet-Bressand, Nataliya Khobta, Julien Bermudez, Youssef Trigui, Laurent Greillier, Marilyne Blanchon, Mohamed Boucekine, Celine Mascaux, Fabrice Barlesi
CLINICAL LUNG CANCER
(2019)
Article
Oncology
Arnaud Jeanson, Arnaud Boyer, Laurent Greillier, Pascale Tomasini, Fabrice Barlesi
EXPERT REVIEW OF ANTICANCER THERAPY
(2019)
Article
Oncology
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solene Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna, Laurent Greillier, Julie Biemar, Isabelle Nanni, L'houcine Ouafik, Stephane Garcia, Julien Mazieres, Fabrice Barlesi, Celine Mascaux
JOURNAL OF THORACIC ONCOLOGY
(2019)
Article
Multidisciplinary Sciences
M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy, S. Benzekry
SCIENTIFIC REPORTS
(2019)
Article
Public, Environmental & Occupational Health
Nathalie Masson, Lionel Dany, Patrice Cannone, Fabrice Barlesi, Marjorie Baciuchka, Pascale Tomasini
PSYCHOLOGY HEALTH & MEDICINE
(2020)
Editorial Material
Oncology
Pascale Tomasini, Laurent Greillier
TRANSLATIONAL LUNG CANCER RESEARCH
(2019)
Article
Psychology, Social
Patrice Cannone, Pascale Tomasini, Merlin Paul, Fabrice Barlesi, Lionel Dany
JOURNAL OF PSYCHOSOCIAL ONCOLOGY
(2019)
Review
Respiratory System
Pascale Tomasini, Julie Egea, Maxime Souquet-Bressand, Laurent Greillier, Fabrice Barlesi
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2019)
Review
Oncology
Laurent Greillier, Pascale Tomasini, Fabrice Barlesi
TRANSLATIONAL LUNG CANCER RESEARCH
(2018)
Review
Respiratory System
Arnaud Boyer, Eddy Pasquier, Pascale Tomasini, Joseph Ciccolini, Laurent Greillier, Nicolas Andre, Fabrice Barlesi, Celine Mascaux
EUROPEAN RESPIRATORY REVIEW
(2018)
